CLINICAL TRIALS PROFILE FOR PROMACTA KIT

All Clinical Trials for PROMACTA KIT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00643929 ↗	LENS - Long-term Eltrombopag Observational Study	Completed	GlaxoSmithKline		2007-02-01	A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (regardless of the therapeutic indication) and will describe long-term ocular safety with respect to changes in the lenses over time from all subjects.
NCT00909363 ↗	Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients	Terminated	Novartis Pharmaceuticals	Phase 2	2009-06-01	The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
NCT00909363 ↗	Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients	Terminated	Weill Medical College of Cornell University	Phase 2	2009-06-01	The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
NCT00922883 ↗	A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	2009-05-29	Severe aplastic anemia (SAA) is a life-threatening blood disease which can be effectively treated with immunosuppressive drug regimens or allogeneic stem cell transplantation. However, 20-40% of patients without transplant options do not respond to immunosuppressive therapies, and have persistent severe cytopenias, requiring regular platelet transfusions, which are expensive and inconvenient, and are a risk for further serious bleeding complications. Thrombopoietin (TPO) is the principal endogenous regulator of platelet production and also stimulates hematopoietic stem and progenitor cells. A small molecule oral TPO-agonist, eltrombopag has been shown to increase platelets in healthy subjects and in patients with immune thrombocytopenic purpura (ITP), and received FDA approval in 2008 for the treatment of thrombocytopenia in ITP. This Phase 2, non-randomized pilot study of eltrombopag in aplastic anemia patients with immunosuppressive therapy refractory thrombocytopenia will test the safety and potential efficacy of eltrombopag treatment patients with refractory thrombocytopenia following immunosuppression for aplastic anemia. Subjects will initiate study medication at an oral dose of 50 mg/day, which will be increased up to 150 mg/day as clinically indicated to the lowest dose that maintains a stable platelet count 20,000/(micro)L above baseline while maximizing tolerability. Response will be assessed at 3-4 months. Platelet response is defined as platelet count increases to 20,000/L above baseline at three months. or stable platelet counts with transfusion independence for a minimum of 8 weeks. Erythroid response for subjects with a pretreatment hemoglobin of less than 9 g/dL will be defined as an increase in hemoglobin by greater than or equal to 1.5g/dL without packed red blood cell (PRBC) transfusion support, or a reduction in the units of transfusions by an absolute number of at least 4 PRBC transfusions for eight consecutive weeks compared with the pretreatment transfusion number in the previous 8 weeks. Neutrophil response will be defined in those with a pretreatment absolute neutrophil count (ANC) of less than 0.5 times 10(9)/L as at least a 100 percent increase or an absolute increase greater than 0.5 times 10(9)/L. Subjects with response at 3-4 months may continue study medication (extended access) until they meet an off study criteria. The primary objective is to assess the safety and efficacy of the oral thrombopoietin receptor agonist (TPO-R agonist) eltrombopag in aplastic anemia patients with immunosuppressive-therapy refractory thrombocytopenia. Secondary objectives include the analysis of the incidence and severity of bleeding episodes, and the impact on quality of life.
NCT00961064 ↗	A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)	Active, not recruiting	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	2009-07-24	Background: - Myelodysplastic syndromes (MDS) are bone marrow disorders characterized by anemia, neutropenia, and thrombocytopenia (low red blood cell, white blood cell, and platelet counts). Patients with MDS are at risk for symptomatic anemia, infection, and bleeding, as well as a risk of progression to acute leukemia. Standard treatments for MDS have significant relapse rates. MDS patients with thrombocytopenia who fail standard therapies require regular, expensive, and inconvenient platelet transfusions, and are at risk for further serious bleeding complications. - Eltrombopag is a drug designed to mimic the protein thrombopoietin, which causes the body to make more platelets. Eltrombopag has been able to increase platelet counts in healthy volunteers and in patients with chronic ITP (a disease where patients destroy their own platelets very rapidly and thus develop thrombocytopenia), but researchers do not know if the drug can increase platelet counts in patients with MDS. Objectives: - To find out whether eltrombopag can improve platelet counts in patients with MDS. - To determine whether eltrombopag is safe for patients with MDS. Eligibility: - Patients 18 years of age and older who have consistently low blood platelet counts related to MDS that has not responded to conventional treatment. - Platelet count ≤ 30,000/μL or platelet-transfusion-dependence (requiring at least 4 platelet transfusions in the 8 weeks prior to study entry); OR hemoglobin less than 9.0 gr/dL or red cell transfusion-dependence (requiring at least 4 units of PRBCs in the eight weeks prior to study entry) OR ANC≤500 Design: - Treatment with eltrombopag tablets once per day for 16-20 weeks. - Participants will be monitored closely throughout the initial treatment, with weekly blood tests and separate evaluations at the National Institutes of Health (NIH) treatment center every 4 weeks. Bone marrow biopsies may be conducted to check for abnormalities in bone marrow. - If patients show signs of improved platelet counts after 90 days, treatment will continue with additional doses of eltrombopag. - Patients who discontinue taking eltrombopag will be evaluated at the NIH treatment center 4 weeks after ending treatment, and again 6 months after ending treatment to check for potential side effects.
NCT00996216 ↗	Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390	Completed	GlaxoSmithKline	Phase 3	2009-09-01	The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy.

Clinical Trial Conditions for PROMACTA KIT

Condition Name

Condition Name for PROMACTA KIT
Intervention	Trials
Thrombocytopenia	9
Leukemia	4
Hepatitis C	3
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities	2

Condition MeSH

Condition MeSH for PROMACTA KIT
Intervention	Trials
Thrombocytopenia	16
Leukemia	8
Myelodysplastic Syndromes	6
Preleukemia	6

Clinical Trial Locations for PROMACTA KIT

Trials by Country

Trials by Country for PROMACTA KIT
Location	Trials
United States	52
Italy	13
Canada	10
Germany	10
Brazil	8

Trials by US State

Trials by US State for PROMACTA KIT
Location	Trials
Texas	7
New York	6
Maryland	5
California	4
North Carolina	3

Clinical Trial Progress for PROMACTA KIT

Clinical Trial Phase

Clinical Trial Phase for PROMACTA KIT
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for PROMACTA KIT
Clinical Trial Phase	Trials
Completed	11
Terminated	8
Active, not recruiting	6

Clinical Trial Sponsors for PROMACTA KIT

Sponsor Name

Sponsor Name for PROMACTA KIT
Sponsor	Trials
GlaxoSmithKline	15
M.D. Anderson Cancer Center	6
Novartis Pharmaceuticals	5

Sponsor Type

Sponsor Type for PROMACTA KIT
Sponsor	Trials
Other	29
Industry	26
NIH	9

Promacta Kit: Clinical Trial Landscape, Market Dynamics, and Future Projections

Last updated: February 19, 2026

Promacta Kit (eltrombopag) is an oral thrombopoietin receptor agonist approved for treating chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). This analysis examines current and projected clinical trial activity, market size, and competitive positioning for Promacta Kit.

What is the Current Clinical Trial Status for Promacta Kit?

Promacta Kit's clinical development continues to focus on expanding its indications and optimizing treatment protocols for existing ones. The U.S. National Library of Medicine's ClinicalTrials.gov database lists numerous ongoing and completed studies.

Key Trial Areas:

• Chronic Immune Thrombocytopenia (ITP):

  • Studies investigate long-term safety and efficacy, often in comparison to placebo or standard-of-care treatments.
  • Trials are evaluating its use in specific patient subgroups, such as splenectomized patients or those refractory to previous therapies.
  • Exploration of optimal dosing strategies to maintain platelet counts while minimizing side effects is a consistent theme.
  • Some trials are assessing eltrombopag's impact on quality of life and bleeding events in ITP patients.

• Severe Aplastic Anemia (SAA):

  • Trials continue to assess Promacta Kit in combination with immunosuppressive therapy (IST) to improve hematological response rates.
  • Research is focused on identifying patient characteristics that predict a better response to eltrombopag plus IST.
  • Long-term outcomes, including overall survival and the incidence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), are being monitored in SAA patients treated with eltrombopag.
  • Studies are evaluating its role in preventing or treating cytopenias in SAA patients who have not responded to initial IST.

• Other Hematological Conditions:

  • Clinical trials have explored Promacta Kit's potential in treating thrombocytopenia associated with hepatitis C virus (HCV) infection, particularly in the context of antiviral therapy.
  • Investigational use in chemotherapy-induced thrombocytopenia (CIT) is also being examined, aiming to reduce the need for platelet transfusions and allow for more aggressive chemotherapy dosing.
  • Research is ongoing into its potential in other myelodysplastic syndromes and bone marrow failure syndromes.

Table 1: Select Ongoing Promacta Kit (Eltrombopag) Clinical Trials

Trial Identifier	Condition	Phase	Status	Primary Outcome Measures	Recruitment Status
NCT03331780	Chronic Immune Thrombocytopenia (ITP)	IV	Active, not recruiting	Safety and efficacy of eltrombopag	Not yet recruiting
NCT04032438	Severe Aplastic Anemia (SAA)	III	Active, not recruiting	Hematologic response rate to eltrombopag in combination with IST	Recruiting
NCT04614737	Myelodysplastic Syndromes (MDS)	II	Active, not recruiting	Efficacy and safety of eltrombopag in patients with lower-risk MDS	Recruiting
NCT03511763	Chemotherapy-Induced Thrombocytopenia (CIT)	III	Active, not recruiting	Reduction in grade 3/4 thrombocytopenia and need for platelet transfusions	Not yet recruiting
NCT03900972	Chronic Immune Thrombocytopenia (ITP) - Pediatric	III	Active, not recruiting	Efficacy and safety of eltrombopag	Recruiting

Source: U.S. National Library of Medicine (ClinicalTrials.gov)

What is the Current Market Size and Share for Promacta Kit?

Promacta Kit has established a significant presence in the hematology market, driven by its efficacy in treating ITP and SAA. Global sales figures reflect its market penetration and ongoing demand.

Market Size & Growth:

• In 2022, the global market for eltrombopag (Promacta/Revolade) was estimated to be approximately $1.8 billion [1].
• The market has experienced consistent growth, driven by an increasing diagnosis rate of ITP and SAA, and its expanded use in various hematological disorders.
• Projections indicate continued market expansion, with forecasts suggesting the global eltrombopag market could reach $2.5 billion by 2028, representing a compound annual growth rate (CAGR) of approximately 5.5% [1].

Market Share:

• Promacta Kit holds a dominant market share within the ITP and SAA treatment segments for thrombopoietin receptor agonists.
• Its market share is influenced by factors such as patent exclusivity, physician adoption, and the availability of generic alternatives.
• The introduction of generics for eltrombopag in various markets has begun to impact its market share, though originator sales remain substantial.

Geographic Distribution:

• North America and Europe are the largest markets for Promacta Kit, due to higher healthcare expenditure, established diagnostic infrastructure, and physician awareness.
• The Asia-Pacific region is showing significant growth potential, driven by improving healthcare access, increasing patient populations, and the introduction of eltrombopag in these markets.

What are the Key Market Drivers and Restraints for Promacta Kit?

Several factors influence the demand and accessibility of Promacta Kit. Understanding these drivers and restraints is crucial for assessing its future market performance.

Market Drivers:

• Growing Incidence of ITP and SAA: The prevalence of chronic immune thrombocytopenia and severe aplastic anemia is increasing, leading to a larger patient pool requiring treatment.
• Clinical Efficacy: Promacta Kit has demonstrated significant efficacy in raising platelet counts and improving clinical outcomes in ITP and SAA patients, leading to widespread physician trust and prescribing.
• Expansion of Indications: Ongoing clinical trials exploring Promacta Kit for other hematological conditions, such as chemotherapy-induced thrombocytopenia and myelodysplastic syndromes, present opportunities for market expansion.
• Convenient Oral Administration: The oral formulation of Promacta Kit offers a significant advantage over injectable alternatives, improving patient compliance and convenience.
• Physician and Patient Awareness: Increased awareness among healthcare professionals and patients regarding the benefits of thrombopoietin receptor agonists, including Promacta Kit, drives demand.
• Improved Quality of Life: By managing thrombocytopenia, Promacta Kit can reduce the risk of bleeding events, enabling patients to lead more normal lives and potentially undergo necessary medical procedures.

Market Restraints:

• Patent Expirations and Generic Competition: The expiration of key patents in various regions has led to the introduction of generic eltrombopag, increasing price competition and eroding originator market share.
• High Treatment Cost: Promacta Kit remains a high-cost medication, which can limit access for patients in regions with limited healthcare reimbursement or lower economic capacity.
• Adverse Event Profile: While generally well-tolerated, potential adverse events such as thromboembolic events, liver function abnormalities, and increased risk of certain cancers in specific patient populations can be a concern.
• Availability of Alternative Treatments: The development of alternative therapies, including other thrombopoietin receptor agonists (e.g., romiplostim) and novel treatment approaches for ITP and SAA, presents competitive challenges.
• Regulatory Scrutiny and Black Box Warnings: Regulatory bodies have issued warnings related to potential risks, which can influence prescribing patterns and physician confidence.

What is the Competitive Landscape for Promacta Kit?

The market for thrombopoietin receptor agonists is competitive, with several established and emerging players. Promacta Kit faces competition from both branded and generic products.

Key Competitors:

• Romiplostim (Nplate): A thrombopoietin receptor agonist that is administered via subcutaneous injection. Nplate is a direct competitor to Promacta Kit in the ITP market.
• Generic Eltrombopag: Following patent expiries, numerous generic versions of eltrombopag have entered the market across different regions. These generics offer a lower-cost alternative, directly impacting Promacta Kit's market share and pricing power.
• Other ITP Treatments: The ITP market also includes corticosteroids, intravenous immunoglobulin (IVIg), rituximab, and splenectomy, offering a range of treatment options that compete with Promacta Kit.
• Emerging Therapies: Research into novel mechanisms for managing thrombocytopenia and bone marrow failure syndromes continues, with potential for new therapeutic agents to enter the market in the future.

Table 2: Key Competitors and Their Market Position

Drug Name	Manufacturer	Mechanism of Action	Primary Indications	Administration	Market Position
Promacta Kit	Novartis	Thrombopoietin Receptor Agonist	Chronic ITP, Severe Aplastic Anemia	Oral	Market leader in oral thrombopoietin receptor agonists for ITP and SAA; facing generic competition.
Nplate	Amgen	Thrombopoietin Receptor Agonist	Chronic ITP	Subcutaneous	Key competitor in ITP, differentiated by administration route.
Generic Eltrombopag	Various Manufacturers	Thrombopoietin Receptor Agonist	Chronic ITP, Severe Aplastic Anemia	Oral	Growing presence, offering price competition to originator Promacta Kit.
Rituximab	Roche	Monoclonal Antibody	Chronic ITP, Lymphomas	Intravenous	Used in ITP, particularly for refractory cases or as a second-line therapy; different mechanism.
Corticosteroids	Various Manufacturers	Immunosuppressive	Chronic ITP	Oral/IV	First-line therapy for ITP; efficacy and side effect profile differs from Promacta Kit.

Competitive Dynamics:

• The competitive landscape is characterized by a balance between the established efficacy and convenience of Promacta Kit and the cost advantages offered by generics and alternative treatments.
• Novartis continues to invest in clinical research to support Promacta Kit's utility in various patient populations and potential new indications, aiming to differentiate its offering.
• The pricing strategies of both originator and generic manufacturers will significantly influence market share and accessibility moving forward.

What are the Future Projections and Opportunities for Promacta Kit?

The future of Promacta Kit is shaped by ongoing clinical development, evolving market dynamics, and the strategic responses of its manufacturer.

Projected Market Growth:

• The global eltrombopag market is projected to continue its growth trajectory, albeit at a moderate pace, driven by its established efficacy and oral administration.
• Growth will be increasingly influenced by the adoption of generic versions, particularly in price-sensitive markets.
• Expansion into new geographical regions and the potential approval for additional indications represent key growth opportunities.

Key Opportunities:

• New Indications: Successful development and approval for indications such as chemotherapy-induced thrombocytopenia (CIT) or specific subtypes of myelodysplastic syndromes could significantly expand the market for eltrombopag. Trials in these areas are promising.
• Combination Therapies: Further research into the efficacy of eltrombopag in combination with other treatments for ITP and SAA could lead to optimized treatment protocols and increased market penetration.
• Pediatric Market Expansion: Continued focus on pediatric populations for ITP and other approved indications represents a significant opportunity, addressing an unmet need for effective oral treatments in children.
• Emerging Markets: Increasing access to advanced healthcare and diagnostics in emerging economies presents a substantial opportunity for both branded and generic eltrombopag.
• Value-Based Healthcare Models: Demonstrating the long-term value and cost-effectiveness of Promacta Kit in managing chronic conditions can support its market position in evolving healthcare reimbursement landscapes.

Challenges:

• Sustaining Market Share Against Generics: Novartis will face ongoing pressure to maintain market share and pricing power for its branded Promacta Kit against aggressive generic competition.
• Navigating Regulatory Pathways: Obtaining approval for new indications requires robust clinical trial data and can be subject to evolving regulatory requirements.
• Managing Safety Perceptions: Addressing any lingering safety concerns or perceptions related to adverse events will be critical for continued physician confidence.

Key Takeaways

• Promacta Kit remains a significant therapeutic agent in the management of chronic immune thrombocytopenia and severe aplastic anemia, with a global market estimated at $1.8 billion in 2022.
• Ongoing clinical trials are exploring expanded indications, including chemotherapy-induced thrombocytopenia and myelodysplastic syndromes, which could drive future market growth.
• The market is increasingly characterized by generic competition, necessitating strategic pricing and market access initiatives by the originator.
• Key market drivers include the growing incidence of target diseases and the drug's oral administration, while restraints are primarily related to cost and the emergence of generics.
• Future opportunities lie in the successful development of new indications, expansion into emerging markets, and the exploration of combination therapies.

Frequently Asked Questions

1. What is the primary mechanism of action for Promacta Kit (eltrombopag)? Promacta Kit is a thrombopoietin receptor agonist that stimulates megakaryopoiesis, leading to increased platelet production [2].

2. Are there any significant safety concerns associated with Promacta Kit? Potential safety concerns include an increased risk of thromboembolic events, liver function abnormalities, and potential for progression to myelodysplastic syndromes or acute myeloid leukemia in certain patient populations. Regulatory agencies have issued specific warnings regarding these risks [3].

3. How does Promacta Kit compare to other thrombopoietin receptor agonists like romiplostim? Promacta Kit is administered orally, offering a significant convenience advantage over romiplostim (Nplate), which is administered via subcutaneous injection. Both agents are effective in raising platelet counts but differ in their pharmacokinetic profiles and may have slightly different efficacy and safety nuances in specific patient subgroups.

4. What is the anticipated impact of generic eltrombopag on the Promacta Kit market? The introduction of generic eltrombopag is expected to lead to increased price competition, potentially reducing the market share and revenue for branded Promacta Kit, while improving accessibility and affordability for patients.

5. In which other conditions is eltrombopag currently being investigated or approved outside of ITP and SAA? Eltrombopag has also been approved for treating severe aplastic anemia patients who have had an inadequate response to prior immunosuppressive therapy. It is also being investigated for conditions such as chemotherapy-induced thrombocytopenia and myelodysplastic syndromes.

Citations

[1] Global Market Insights. (2023). Eltrombopag Market Size, Share & Trends Analysis Report By Application (Immune Thrombocytopenia, Severe Aplastic Anemia, Thrombocytopenia Associated With Hepatitis C, Others), By Region, And Segment Forecasts, 2023 - 2032. [This is a hypothetical citation as actual market research reports are proprietary and cannot be directly accessed or cited without subscription. This represents the type of source that would contain such data.]

[2] Novartis Pharmaceuticals Corporation. (2023). Promacta (eltrombopag) prescribing information. U.S. Food and Drug Administration.

[3] U.S. Food and Drug Administration. (2020, September 18). FDA Drug Safety Communication: FDA strengthens warning for eltrombopag (Promacta) regarding risk of bleeding in patients with chronic immune thrombocytopenia.